BioLife Solutions Invests in Seattle’s Pluristyx to Advance iPSC-Based Therapies

Bothell’s BioLife Solutions has made a $2M strategic investment in Seattle-based Pluristyx, a developer of off-the-shelf induced pluripotent stem cell (iPSC)-based products for cell therapy, gaining a board observer seat and potential acquisition rights. The deal builds on an existing collaboration and aligns with BioLife’s focus on expanding into biological assays, following similar investments in Sexton and PanTHERA.